Search

Your search keyword '"Knill, Andrew"' showing total 3 results
Start Over Author "Knill, Andrew" Topic rhinitis
3 results on '"Knill, Andrew"'

1. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management.

Author

Bachert C, Han JK, Wagenmann M, Hosemann W, Lee SE, Backer V, Mullol J, Gevaert P, Klimek L, Prokopakis E, Knill A, Cavaliere C, Hopkins C, and Hellings P

Subjects
Chronic Disease, Congresses as Topic, Humans, Practice Guidelines as Topic, Severity of Illness Index, Nasal Polyps classification, Nasal Polyps diagnosis, Nasal Polyps immunology, Nasal Polyps therapy, Rhinitis classification, Rhinitis diagnosis, Rhinitis immunology, Rhinitis therapy, Sinusitis classification, Sinusitis diagnosis, Sinusitis immunology, Sinusitis therapy
Abstract

Uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) is the most bothersome phenotype of chronic rhinosinusitis; it is typically characterized by a type 2 inflammatory reaction and by comorbidities, including asthma, nonsteroidal anti-inflammatory drug-exacerbated respiratory disease, and allergies. Here, the European Forum for Research and Education in Allergy and Airway Diseases proposes structured definitions to enable communication between clinicians and provides a practical algorithm to define type 2 inflammation in CRSwNP in daily clinical practice. A rational approach for the treatment of uncontrolled severe CRSwNP is discussed; it consists of evaluating the perspective and risks of surgery and efficacy and adverse events of biologics on the basis of currently available data. Further, possible combinations of surgery and biologics are discussed, and a rationale is provided. Here, it is of importance to adequately counsel the patient about both approaches to enable a decision-making process with an informed patient. Criteria for the selection of a biologic drug are provided, as several biologics for uncontrolled severe CRSwNP will be available in many countries within a short time. Further, suggestions for monitoring of the drug effects that support recognition of responders to the therapy and, subsequently, the decision regarding continuation or discontinuation of the biologic are proposed., (Copyright © 2020. Published by Elsevier Inc.)

Published
2021
Full Text
View/download PDF

2. EUFOREA consensus on biologics for CRSwNP with or without asthma.

Author

Fokkens WJ, Lund V, Bachert C, Mullol J, Bjermer L, Bousquet J, Canonica GW, Deneyer L, Desrosiers M, Diamant Z, Han J, Heffler E, Hopkins C, Jankowski R, Joos G, Knill A, Lee J, Lee SE, Mariën G, Pugin B, Senior B, Seys SF, and Hellings PW

Subjects
Biological Products administration & dosage, Biological Products adverse effects, Chronic Disease, Clinical Decision-Making, Comorbidity, Disease Management, Health Services Needs and Demand, Humans, Research, Treatment Outcome, Asthma complications, Biological Products therapeutic use, Nasal Polyps complications, Rhinitis complications, Rhinitis drug therapy, Sinusitis complications, Sinusitis drug therapy
Abstract

Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of patients with asthma show a type 2 inflammatory signature in sinonasal mucosa and/or lungs. Importantly, both chronic respiratory diseases are frequent comorbidities, ensuring alleviation of both upper and lower airway pathology by systemic biological therapy. Type 2-targeting biologics such as anti-IgE, anti-IL4Rα, anti-IL5, and anti-IL5Rα have entered the market for selected pheno/endotypes of asthma patients and may soon also become available for CRSwNP patients. Given the high prevalence of chronic respiratory diseases and the high cost associated with biologics, patient selection is crucial in order to implement such therapies into chronic respiratory disease care pathways. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) organized a multidisciplinary Expert Board Meeting to discuss the positioning of biologics into the care pathways for CRSwNP patients with and without comorbid asthma., (© 2019 The Authors Allergy Published by John Wiley & Sons Ltd.)

Published
2019
Full Text
View/download PDF

3. European Position Paper on Rhinosinusitis and Nasal Polyps 2020

Author

Fokkens, Wytske, Lund, Valerie, Hopkins, Claire, Hellings, Peter, Kern, Robert, Reitsma, Sietze, Toppila- Salmi, Sanna, Bernal-Sprekelsen, Manuel, Mullol, Joaquim, Alobid, Isam, Anselmo- Lima, Wilma Terezinha, Bachert, Claus, Baroody, Fuad, von Buchwald, Christian, Cervin, Anders, Cohen, Noam, Constantinidis, Jannis, De Gabory, Ludovic, Desrosiers, Martin, Diamant, Zuzana, Douglas, Richard, Gevaert, Philippe, Hafner, Anita, Harvey, Richard, Joos, Guy, Kalogjera, Livije, Knill, Andrew, Kocks, Janwillem, Landis, Basile, Limpens, Jacqueline, Lebeer, Sarah, Lourenco, Olga, Matricardi, Paolo, Meco, Cem, O’Mahony, Liam, Philpott, Carl, Ryan, Dermot, Schlosser, Rodney, Senior, Brent, Smith, Timothy, Teeling, Thijs, Tomazic, Peter Valentin, Wang, De Yun, Wang, Dehui, Zhang, Luo, Agius, Adrian, Ahlström-Emanuelsson, Cecilia, Alabri, Rashid, Albu, Silviu, Alhabash, Saied, Aleksic, Aleksandra, Aloulah, Mohammad, Al- Qudah, Mohannad, Alsaleh, Saad, Baban, Muaid Aziz, Baudoin, Tomislav, Balvers, Tijmen, Battaglia, Paolo, Bedoya, Juan David, Beule, Achim, Bofares, Khaled, Braverman, Itzhak, Brozek-Madry, Eliza, Byaruhanga, Richard, Callejas, Claudio, Carrie, Sean, Caulley, Lisa, Chussi, Desderius, de Corso, Eugenio, Coste, Andre, El Hadi, Usama, Elfarouk, Ahmed, Eloy, Philippe, Farrokhi, Shokrollah, Felisati, Giovanni, Ferrari, Michel, Fishchuk, Roman, Grayson, Jessica, Goncalves, Paulo, Grdinic, Boris, Grgic, Velimir, Hamizan, Aneeza, Heinichen, Julio, Husain, Salina, Ing Ping, Tang, Ivaska, Justinas, Jakimovska, Frodita, Jovancevic, Ljiljana, Kakande, Emily, Kamel, Reda, Karpischenko, Sergei, Kariyawasam, Harsha, Kawauchi, Hideyuki, Kjeldsen, Anette, Klimek, Ludger, Krzeski, Antoni, Kopacheva Barsova, Gabriela, Wam Kim, Sung, Lal, Devyani, Letort, José, Lopatin, Andrey, Mahdjoubi, Abdelhak, Mesbahi, Alireza, Netkovski, Jane, Nyenbue Tshipukane, Dieudonné, Obando-Valverde, Andrés, Okano, Mitsuhiro, Onerci111, Metin, Ong, Yew Kwang, Orlandi, Richard, Otori, Nobuyoshi, Ouennoughy, Kheir, Ozkan, Muge, Peric, Aleksandar, Plzak, Jan, Prokopakis, Emmanuel, Prepageran, Nerayanan, Psaltis, Alkis, Pugin, Benoit, Raftopulos, Marco, Rombaux, Philippe, Riechelmann, Herbert, Sahtout, Semia, Sarafoleanu, Caius-Codrut, Searyoh, Kafui, Rhee, Chae-Seo, Shi, Jianbo, Shkoukani, Mahdi, Shukuryan, Arthur, Sicak, Marian, Smyth, David, Snidvongs, Kornkiat, Soklic Kosak, Tanja, Stjärne, Pär, Sutikno, Budi, Steinsvåg, Sverre, Tantilipikorn, Pongsakorn, Thanaviratananich, Sanguansak, Tran, Thuy, Urbancic, Jure, Valiulis, Arunas, Vasquez de Aparicio, Carolina, Vicheva, Dilyana, Virkkula, Paula, Vicente, Gil, Voegels, Richard, Wagenmann, Martin, Wardani, Retno, Welge-Lussen, Antje, Witterick, Ian, Wright, Erin, Zabolotniy, Dmytro, Zsolt, Bella, Zwetsloot, Casper, HUS Inflammation Center, Department of Dermatology, Allergology and Venereology, University of Helsinki, Korva-, nenä- ja kurkkutautien klinikka, HUS Head and Neck Center, uBibliorum, Faculteit Medische Wetenschappen/UMCG, Fokkens, Wytske J., UCL - (MGD) Service d'oto-rhino-laryngologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service d'oto-rhino-laryngologie, Ear, Nose and Throat, and AII - Inflammatory diseases

Subjects
Adult, medicine.medical_specialty, Evidence-based practice, Rhinosinusitis, MEDLINE, Therapeutics, PLACEBO-CONTROLLED TRIAL, 03 medical and health sciences, 0302 clinical medicine, Nasal Polyps, QUALITY-OF-LIFE, Diagnosis, paranasal sinus diseases, nasal polyps, therapeutics, diagnosis, asthma, prevention, control, Paranasal Sinus Diseases, Humans, Medicine, Nasal polyps, ENDOSCOPIC-SINUS-SURGERY, 3125 Otorhinolaryngology, ophthalmology, Sinusitis, Prevention and Control, Child, 030223 otorhinolaryngology, Intensive care medicine, UPPER RESPIRATORY-TRACT, TERM-FOLLOW-UP, Rhinitis, Science & Technology, business.industry, General Medicine, Guideline, Evidence-based medicine, RANDOMIZED CONTROLLED-TRIAL, medicine.disease, ACUTE MAXILLARY SINUSITIS, Asthma, 3. Good health, Integrated care, CHURG-STRAUSS-SYNDROME, Otorhinolaryngology, Acute Disease, Chronic Disease, Position paper, PRIMARY CILIARY DYSKINESIA, Human medicine, business, ALLERGIC FUNGAL RHINOSINUSITIS, Life Sciences & Biomedicine
Abstract

The European Position Paper on Rhinosinusitis and Nasal Polyps 2020 is the update of similar evidence based position papers published in 2005 and 2007 and 2012. The core objective of the EPOS2020 guideline is to provide revised, up-to-date and clear evidence-based recommendations and integrated care pathways in ARS and CRS. EPOS2020 provides an update on the literature published and studies undertaken in the eight years since the EPOS2012 position paper was published and addresses areas not extensively covered in EPOS2012 such as paediatric CRS and sinus surgery. EPOS2020 also involves new stakeholders, including pharmacists and patients, and addresses new target users who have become more involved in the management and treatment of rhinosinusitis since the publication of the last EPOS document, including pharmacists, nurses, specialised care givers and indeed patients themselves, who employ increasing self-management of their condition using over the counter treatments. The document provides suggestions for future research in this area and offers updated guidance for definitions and outcome measurements in research in different settings. EPOS2020 contains chapters on definitions and classification where we have defined a large number of terms and indicated preferred terms. A new classification of CRS into primary and secondary CRS and further division into localized and diffuse disease, based on anatomic distribution is proposed. There are extensive chapters on epidemiology and predisposing factors, inflammatory mechanisms, (differential) diagnosis of facial pain, allergic rhinitis, genetics, cystic fibrosis, aspirin exacerbated respiratory disease, immunodeficiencies, allergic fungal rhinosinusitis and the relationship between upper and lower airways. The chapters on paediatric acute and chronic rhinosinusitis are totally rewritten. All available evidence for the management of acute rhinosinusitis and chronic rhinosinusitis with or without nasal polyps in adults and children is systematically reviewed and integrated care pathways based on the evidence are proposed. Despite considerable increases in the amount of quality publications in recent years, a large number of practical clinical questions remain. It was agreed that the best way to address these was to conduct a Delphi exercise . The results have been integrated into the respective sections. Last but not least, advice for patients and pharmacists and a new list of research needs are included. The full document can be downloaded for free on the website of this journal: http://www.rhinologyjournal.com. ispartof: RHINOLOGY vol:58 issue:Suppl S29 pages:I-+ ispartof: location:Netherlands status: published

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results